Related references
Note: Only part of the references are listed.Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection
Tobias Deuse et al.
TRANSPLANTATION (2008)
Selective predisposition to bacterial infections in IRAK-4-deficient children:: IRAK-4-dependent TLRs are otherwise redundant in protective immunity
Cheng-Lung Ku et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib
Oliver Hantschel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Development of Rho-kinase inhibitors for cardiovascular medicine
Hiroaki Shimokawa et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Protein kinase C theta (PKCθ):: A key player in T cell life and death
Keitaro Hayashi et al.
PHARMACOLOGICAL RESEARCH (2007)
Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor- mediated immune responses but not in TCR signaling
Tatsukata Kawagoe et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity
Tae Whan Kim et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and toll-like receptor 7-mediated signaling and gene expression
Magdalena Koziczak-Holbro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Interleukin-1 (IL-1)-induced TAK1-dependent versus MEKK3-dependent NFκB activation pathways bifurcate at IL-1 receptor-associated kinase modification
Jianhong Yao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Therapeutic potential of Rho-kinase inhibitors in asthma
Xi-Qian Xing et al.
MEDICAL HYPOTHESES (2007)
Discovery of potent and selective PKC-theta inhibitors
Charles L. Cywin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma
Vasantha P. Rao et al.
BIODRUGS (2007)
Crystal structures of IRAK-4 kinase in complex with inhibitors: A serine/threonine kinase with tyrosine as a gatekeeper
Zhulun Wang et al.
STRUCTURE (2006)
Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases
Karen Anderson et al.
AUTOIMMUNITY (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors
Tsung H. Lin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Long-term administration of Rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats
Yayoi Ishikawa et al.
HYPERTENSION (2006)
Progress and problems in the exploration of therapeutic targets
Chanjuan Zheng et al.
DRUG DISCOVERY TODAY (2006)
A critical role for the innate immune signaling molecule IRAK-4 in T cell activation
N Suzuki et al.
SCIENCE (2006)
Rho kinases in cardiovascular physiology and pathophysiology
G Loirand et al.
CIRCULATION RESEARCH (2006)
Molecular mechanisms and therapeutic strategies of chronic renal injury: Renoprotective effect of Rho-kinase inhibitor in hypertensive glomerulosclerosis
T Nishikimi et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2006)
Therapies for rheumatoid arthritis: hope springs eternal
RJ Smith
DRUG DISCOVERY TODAY (2005)
Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges
E Hu et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis
A Rubins et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
Protein kinase C θ is not essential for T-Cell-Mediated clearance of murine gammaherpesvirus 68
F Giannoni et al.
JOURNAL OF VIROLOGY (2005)
Rho kinase, a promising drug target for neurological disorders
BK Mueller et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
RhoE function is regulated by ROCK I-mediated phosphorylation
K Riento et al.
EMBO JOURNAL (2005)
ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles
Y Shimizu et al.
JOURNAL OF CELL BIOLOGY (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
CW Lindsley et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Bruton's tyrosine kinase:: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling
JM Lindvall et al.
IMMUNOLOGICAL REVIEWS (2005)
A Rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia. bronchoconstriction and airways hyperresponsiveness in allercric mice.
PJ Henry et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2005)
Involvement of RhoA-mediated Ca2+ sensitization in antigen-induced bronchial smooth muscle hyperresponsiveness in mice -: art. no. 4
Y Chiba et al.
RESPIRATORY RESEARCH (2005)
The discovery of novel chemotypes of p38 kinase inhibitors
DJ Diller et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2005)
PKCθ signals activation versus tolerance in vivo
NN Berg-Brown et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
The role of interleukin 1 receptor-associated kinase-4 (IRAK-4) kinase activity in IRAK-4-mediated signaling
E Lye et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model
M Cetkovic-Cvrlje et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses
A Mangla et al.
BLOOD (2004)
Protein kinase C θ is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses
BJ Marsland et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Rho signaling in vascular diseases
TM Seasholtz et al.
MOLECULAR INTERVENTIONS (2004)
Perspectives on PKCθ in T cell activation
CE Sedwick et al.
MOLECULAR IMMUNOLOGY (2004)
Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK)
AO Vassilev et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
Growth factor-induced contraction of human bronchial smooth muscle is Rho-kinase-dependent
R Gosens et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness
JZ Qin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models
E Kudlacz et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
An efficient proteomics method to identify the cellular targets of protein kinase inhibitors
K Godl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
PS Changelian et al.
SCIENCE (2003)
The anti-leukemic Bruton's tyrosine kinase inhibitor α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism
FM Uckun et al.
LEUKEMIA & LYMPHOMA (2003)
p38 map kinases: Key signalling molecules as therapeutic targets for inflammatory diseases
S Kumar et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections
AE Medvedev et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases
LA O'Neill
CURRENT OPINION IN PHARMACOLOGY (2003)
Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death
D Thumkeo et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor at production
NJ Horwood et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Protein kinase C θ affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells
C Pfeifhofer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Rocks: Multifunctional kinases in cell behaviour
K Riento et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Pyogenic bacterial infections in humans with IRAK-4 deficiency
C Picard et al.
SCIENCE (2003)
Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members
S Janssens et al.
MOLECULAR CELL (2003)
p38 MAP kinase inhibitors.: Part 1:: Design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold
SR Natarajan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia
PA Goodman et al.
LEUKEMIA & LYMPHOMA (2003)
Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA)
JE Heinonen et al.
FEBS LETTERS (2002)
The druggable genome
AL Hopkins et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Protein kinase Cδ controls self-antigen-induced B-cell tolerance
I Mecklenbräuker et al.
NATURE (2002)
Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ
A Miyamoto et al.
NATURE (2002)
Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4
N Suzuki et al.
NATURE (2002)
IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase
SY Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
C Pargellis et al.
NATURE STRUCTURAL BIOLOGY (2002)
The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway
Y Sasaki et al.
PHARMACOLOGY & THERAPEUTICS (2002)
Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin
SM Stepkowski et al.
BLOOD (2002)
Four tyrosine residues in phospholipase C-γ2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling
D Watanabe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy
IM McLay et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2001)
Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase
WN Khan
IMMUNOLOGIC RESEARCH (2001)
Regulation of the Jak2 tyrosine kinase by its pseudokinase domain
P Saharinen et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes
ZM Sun et al.
NATURE (2000)
Deficiency of the stress kinase p38α results in embryonic lethality:: Characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells
M Allen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains
M Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
